These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36605482)

  • 1. Integrative Analysis Identified CD38 As a Key Node That Correlates Highly with Immunophenotype, Chemoradiotherapy Resistance, And Prognosis of Head and Neck Cancer.
    He Z; Yue C; Chen X; Li X; Zhang L; Tan S; Yi X; Luo G; Zhou Y
    J Cancer; 2023; 14(1):72-87. PubMed ID: 36605482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic signature associated with radioresistance in head and neck cancer via transcriptomic and bioinformatic analyses.
    You GR; Cheng AJ; Lee LY; Huang YC; Liu H; Chen YJ; Chang JT
    BMC Cancer; 2019 Jan; 19(1):64. PubMed ID: 30642292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of chemokine CXCL8/9/10/11/13 and its prognostic significance in head and neck cancer.
    Zhao Z; Ma Y; Lv J; Maimaiti N; Zhang J; Aibibula M; Gong Z; Ling B
    Medicine (Baltimore); 2022 Jul; 101(30):e29378. PubMed ID: 35905218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials.
    Huang Z; Zheng S; Ding S; Wei Y; Chen C; Liu X; Li H; Xia Y
    J Cancer Res Ther; 2021 Jul; 17(3):676-687. PubMed ID: 34269299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying potential prognostic biomarkers in head and neck cancer based on the analysis of microRNA expression profiles in TCGA database.
    Wang X; Yin Z; Zhao Y; He M; Dong C; Zhong M
    Mol Med Rep; 2020 Mar; 21(3):1647-1657. PubMed ID: 32016476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis.
    Li J; Wang P; Xu Y
    PLoS One; 2017; 12(6):e0179536. PubMed ID: 28604812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Interplays Between Cell Invasion and Radioresistance That Lead to Poor Prognosis in Head-Neck Cancer.
    You GR; Chang JT; Li YL; Chen YJ; Huang YC; Fan KH; Chen YC; Kang CJ; Cheng AJ
    Front Oncol; 2021; 11():681717. PubMed ID: 34307149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive analysis of the expression and prognosis for TNFAIPs in head and neck cancer.
    Lan G; Yu X; Sun X; Li W; Zhao Y; Lan J; Wu X; Gao R
    Sci Rep; 2021 Aug; 11(1):15696. PubMed ID: 34344926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma.
    Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y
    World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of fatty acid metabolism-related molecular subtype biomarkers and their correlation with immune checkpoints in cutaneous melanoma.
    Xu Y; Chen Y; Jiang W; Yin X; Chen D; Chi Y; Wang Y; Zhang J; Zhang Q; Han Y
    Front Immunol; 2022; 13():967277. PubMed ID: 36466837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and prognostic potential of PLEK2 in head and neck squamous cell carcinoma based on bioinformatics analysis.
    Wang J; Sun Z; Wang J; Tian Q; Huang R; Wang H; Wang X; Han F
    Cancer Med; 2021 Sep; 10(18):6515-6533. PubMed ID: 34331382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Diagnostic and Prognostic Value of sIL-2R as an Immune Biomarker in Head and Neck Cancers.
    Gross M; Meirovich A; Rachmut J; Kalichman I; Peretz T; Eliashar R; Barak V
    Anticancer Res; 2016 Aug; 36(8):4347-52. PubMed ID: 27466555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Landscape of Iron Metabolism-Related and Methylated Genes in the Prognosis Prediction of Clear Cell Renal Cell Carcinoma.
    Mou Y; Zhang Y; Wu J; Hu B; Zhang C; Duan C; Li B
    Front Oncol; 2020; 10():788. PubMed ID: 32528886
    [No Abstract]   [Full Text] [Related]  

  • 14. LPAR2 correlated with different prognosis and immune cell infiltration in head and neck squamous cell carcinoma and kidney renal clear cell carcinoma.
    Sun K; Chen RX; Li JZ; Luo ZX
    Hereditas; 2022 Mar; 159(1):16. PubMed ID: 35241179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SPP1 as a key gene in the lymph node metastasis and a potential predictor of poor prognosis in head and neck carcinoma.
    Feng S; Yuan W; Sun Z; Guo X; Ling J; Chang A; Zhao H; Zhuo X
    J Oral Pathol Med; 2022 Aug; 51(7):620-629. PubMed ID: 35822409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of hub genes involved in cisplatin resistance in head and neck cancer.
    Chaudhary RK; Khanal P; Mateti UV; Shastry CS; Shetty J
    J Genet Eng Biotechnol; 2023 Jan; 21(1):9. PubMed ID: 36715825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pseudogene Transcripts in Head and Neck Cancer: Literature Review and
    Carron J; Della Coletta R; Lourenço GJ
    Genes (Basel); 2021 Aug; 12(8):. PubMed ID: 34440428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Cluster and PPI Network Analyses Identified CXCR3 as a Key Node of Immunoregulation in Head and Neck Cancer.
    Wang P; Wang Y; Jiang Y; Li M; Li G; Qiao Q
    Front Oncol; 2020; 10():564306. PubMed ID: 33585188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. POPDC3 is a potential biomarker for prognosis and radioresistance in patients with head and neck squamous cell carcinoma.
    He X; Xu H; Zhao W; Zhan M; Li Y; Liu H; Tan L; Lu L
    Oncol Lett; 2019 Nov; 18(5):5468-5480. PubMed ID: 31612055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant chemotherapy with S-1 after curative chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck: Reanalysis of the ACTS-HNC study.
    Kubota A; Nakatani E; Tsukahara K; Hasegawa Y; Takemura H; Terada T; Taguchi T; Nagahara K; Nakatani H; Yoshino K; Higaki Y; Iwae S; Beppu T; Hanamure Y; Tomita K; Kohno N; Kawabata K; Teramukai S; Fujii M;
    PLoS One; 2018; 13(6):e0198391. PubMed ID: 29883463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.